Newborn screening for cystic fibrosis.
Newborn screening for cystic fibrosis (CF) was considered over 3 decades ago in 1970; however, the technology did not exist then for an accurate neonatal screening test. With the development of immunoreactive trypsinogen analysis, alone or coupled with DNA mutation analysis, the means were developed for CF newborn screening. Studies have demonstrated benefits of newborn screening in the areas of nutrition, cognitive function, pulmonary function, and survival.
Rock
Michael J
MJ
Division of Pediatric Pulmonology, University of Wisconsin Hospital and Clinics, 600 Highland Avenue, Room K4/946, Madison, WI 53792, USA. mjrock@wisc.edu
D002986:Clinical Trials as Topic; D003072:Cognition Disorders / Q000517:prevention & control; D003362:Cost-Benefit Analysis; D003550:Cystic Fibrosis / Q000175:diagnosis*; D005820:Genetic Testing / Q000379:methods; D006801:Humans; D007231:Infant, Newborn; D015997:Neonatal Screening / Q000191:economics / Q000379:methods*; D018529:Nutritional Support; D012129:Respiratory Function Tests; D015996:Survival Rate; D014362:Trypsinogen / Q000032:analysis
D014362:Trypsinogen